Posted by Michael Wonder on 08 Dec 2022
Takeda’s Qdenga (dengue tetravalent vaccine [live, attenuated]) approved for use in European Union
8 December 2022 - Qdenga becomes the only dengue vaccine approved in the EU for use in individuals regardless of previous dengue exposure.
Takeda today announced that the European Commission granted marketing authorisation for the company’s dengue vaccine Qdenga (dengue tetravalent vaccine [live, attenuated]) (TAK-003) for the prevention of dengue disease in individuals from four years of age in the European Union.
